Announcement • Feb 19
Protagenic Therapeutics, Inc. announced delayed 10-Q filing On 02/18/2026, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Jan 16
Nasdaq Stock Market to Delist Common Stock of Protagenic Therapeutics, Inc The Nasdaq Stock Market announced that it will delist the common stock, and warrants of Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc.’s securities were suspended on January 5, 2026 and have not traded on Nasdaq since that time. Announcement • Jan 05
Protagenic Therapeutics Receives Delisting Notice from Nasdaq Beginning January 5, 2026, Protagenic Therapeutics, Inc. (the Company") expects its common stock (PTIX") and warrants (PTIXW") to be quoted for trading on the over-the-counter market. On December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (Nasdaq") stating that trading of the Company's securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company's securities based on the Company's failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is generally available through brokerage platforms and publicly available quotation services. The Company intends to continue to file periodic and current reports with the SEC, which will be available on the SEC's EDGAR system. The OTC market may have different liquidity and trading characteristics than a national securities exchange. The Company is evaluating steps to regain compliance with Nasdaq listing requirements and to seek relisting on Nasdaq. The Company also intends to engage with market participants to facilitate the OTC transition and support liquidity in its securities. The Company has withdrawn its request for a hearing before a Nasdaq Hearings Panel and, accordingly, Nasdaq's determination is final. 
